Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Resorberbara Stödstrukturer med everolimus-Eluering för Behandling av Infrapopliteal Artärsjukdom hos Patienter med Kronisk Livshotande Ischemi i Extremitet (RESCUE)

Resorberbara Scaffolds med everolimus-Eluering för Behandling av Infrapopliteal Artärsjukdom hos Patienter med Kronisk Livshotande Ischemi i Extremitet

RESCUE is a Europe-wide study that will follow 400 people with critical limb-threatening ischemia (CLTI). It aims to see how well Esprit BTK™ Everolimus Eluting Resorbable Scaffolds work in real-life medical settings. The study focuses on people who have heavily calcified arteries in the infrapopliteal areas of the leg.

These drug-eluting resorbable scaffolds release a medication that helps prevent the inner wall of the blood vessel from thickening after injury or surgery. This can reduce the chance of the artery becoming blocked again (a problem called restenosis), while also giving temporary structural support to the vessel. Over time, the scaffold naturally dissolves in the body, which may lower the long-term risks associated with permanent metal stents.

Studieöversikt

Studietyp

Observationell

Inskrivning (Beräknad)

400

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

  • Namn: Claire Poulet, PhD
  • Telefonnummer: +41 79 385 16 78
  • E-post: oracue@cirse.org

Studera Kontakt Backup

  • Namn: Dhwani S. Korde, PhD
  • Telefonnummer: +4367762942469
  • E-post: oracue@cirse.org

Studieorter

      • Hull, Storbritannien, HU3 2JZ
        • Rekrytering
        • Hull University Teaching Hospitals NHS Trust
        • Huvudutredare:
          • Raghu Lakshminarayan, Dr

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Adult CLTI patients treated with the Esprit BTK everolimus-eluting resorbable scaffold following adequate vessel preparation for infrapopliteal artery disease.

Beskrivning

Inclusion Criteria:

  1. Rutherford classification category ≥4;
  2. Treatment of infrapopliteal lesions with the Esprit BTK everolimus eluting resorbable scaffold system following adequate vessel preparation;
  3. Calcification of target lesions must be visible on fluoroscopy or CT-angiography;
  4. Patients competent and willing to provide informed consent.

Exclusion Criteria:

  1. Minors and other vulnerable populations who may not be able to give informed consent freely or for whom participation is not essential to the study (incapacitated and unconscious individuals, persons deprived of liberty, pregnant and breastfeeding women, etc.);
  2. Inadequate inflow (>30% stenosis) following optimization;
  3. Insufficient direct outflow (less than 1 run-off vessel);
  4. Endovascular procedure(s) on the treatment site within 4 weeks before index procedure;
  5. Patients planned to receive an above ankle amputation of the target limb;
  6. Patients enrolled in ORACLE (ClinicalTrials.gov ID NCT07270562).

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Adult CLTI patients with infrapopliteal calcified lesions

Adult CLTI patients planned to receive the Esprit BTK™ resorbable scaffold following pre-dilatation with angioplasty balloon.

The Esprit BTK™ is a bioresorbable vascular scaffold designed for arteries below the knee. It provides temporary support to keep the vessel open while releasing everolimus-an antiproliferative drug that helps prevent excessive tissue growth and reduces the risk of restenosis. As the scaffold delivers the medication, it gradually dissolves, potentially lowering long-term risks associated with permanent stents.

Andra namn:
  • Läkemedelsavgivande resorberbar stentgaller

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Number of lesions free from Clinically-Driven Target Lesion Revascularization (CD-TLR)
Tidsram: 12 months

Defined as freedom from any endovascular re-intervention to the target lesion (± 10 mm) or surgical bypass performed because of restenosis or occlusion of the target lesion.

12 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
CD-TLR-free survival per target lesion
Tidsram: Until the end of the follow-up period of 3 years

Defined as the time between first index procedure and any endovascular re-intervention to the target lesion (± 10 mm) or surgical bypass performed because of restenosis or occlusion of the target lesion.

Until the end of the follow-up period of 3 years
Clinical response using Rutherford classification categories
Tidsram: 12, 24, and 36 months

The Rutherford classification is a clinical scale used to categorize the severity of peripheral arterial disease: Category 0 = asymptomatic; Category 1 = mild claudication; Category 2 = moderate claudication; Category 3 = severe claudication; Category 4 = ischemic rest pain; Category 5 = minor tissue loss; Category 6 = severe tissue loss.

12, 24, and 36 months
Wound status
Tidsram: 12, 24, and 36 months

Defined as healing status of the dominant ischemic wound of the target limb (complete, partial, unchanged, worsening).

12, 24, and 36 months
Freedom from major amputation of the target limb
Tidsram: 12 and 24 months

Defined as absence of any amputation of the target limb (above ankle).

12 and 24 months
Amputation-free survival
Tidsram: Until the end of the follow-up period of 3 years

Defined as time between first index procedure and amputation of the target limb, minor (digital, metatarsal), major below the knee or major above the knee (excluding any amputation planned before the index procedure).

Until the end of the follow-up period of 3 years
Overall survival
Tidsram: Until the end of the follow-up period of 3 years

Defined as the time between the first index procedure and death of any cause.

Until the end of the follow-up period of 3 years
Patient-reported health-related quality-of-life
Tidsram: Baseline, Day 0 (day of procedure), 6-, 12-, 24-, 26-months post treatment

Measured by Vascular Quality of Life Questionnaire - 6 items (VascuQol-6), which is a short patient-reported outcome measure (PROM), used to assess health-related quality of life in people with PAD. It consists of 6 questions, each scored from 1 to 7, with 1 as the worst possible quality of life and 7 as the best possible quality of life. Higher overall scores reflect better quality of life for patients with PAD.

Baseline, Day 0 (day of procedure), 6-, 12-, 24-, 26-months post treatment
Frequency and severity of procedural complications and other adverse events
Tidsram: Within 30 days after the index procedure

Grading according to the classification system of the Cardiovascular and Interventional Radiological Society of Europe.

Within 30 days after the index procedure
Frequency of major adverse limb events (MALE) and peri-operative death (POD).
Tidsram: 6 months for MALE; Within 30 days after the index procedure for POD

MALE include above-ankle amputation in the index limb, major re-intervention on the index limb at 6 months and POD includes perioperative (30-day) mortality.

6 months for MALE; Within 30 days after the index procedure for POD
Clinical response using ankle-brachial index (ABI)
Tidsram: 12, 24, and 36 months

The ankle-brachial index (ABI) is a non-invasive measure calculated as the ratio of systolic blood pressure at the ankle to systolic blood pressure at the arm. ABI categories commonly used to classify peripheral arterial disease are: >1.40 = non-compressible arteries; 1.00-1.40 = normal; 0.91-0.99 = borderline; 0.41-0.90 = mild to moderate peripheral arterial disease; <0.40 = severe peripheral arterial disease.

12, 24, and 36 months
Clinical response using toe pressure
Tidsram: 12, 24, and 36 months

The toe pressure test measures distal limb perfusion by recording systolic pressure at the toe. In CLTI patients, toe pressure ≤30 mmHg is commonly used to indicate severe ischemia, while values >30 mmHg suggest better perfusion.

12, 24, and 36 months
Clinical response using WIfi (wound, ischemia and foot infection) score
Tidsram: 12, 24, and 36 months

The WIfI classification is a staging system used to assess CLTI based on wound extent, ischemia severity, and foot infection. Each component is graded from 0 (none) to 3 (severe). Lower WIfI scores indicate a lower risk of limb loss and a lesser urgency for revascularization, whereas higher scores indicate greater disease severity, higher amputation risk, and greater potential benefit from revascularization.

12, 24, and 36 months
Restoration of normal lumen per target lesion
Tidsram: Immediately upon procedure completion

Defined as residual stenosis ≤30%, immediately after completion of full planned procedure.

Immediately upon procedure completion

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Samarbetspartners

Utredare

  • Studiestol: Gerd Grözinger, Prof. Dr. med., SLK Kliniken Heilbronn GmbH
  • Studiestol: Marianne Brodmann, Univ.-Prof. Dr. med., Medizinische Universität Graz
  • Studiestol: Raghu Lakshminarayan, Dr, Hull University Teaching Hospital
  • Studiestol: Stefan Müller-Hülsbeck, Prof. Dr. med., DIAKO Krankenhaus gGmBH

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

31 augusti 2026

Primärt slutförande (Beräknad)

1 augusti 2032

Avslutad studie (Beräknad)

1 december 2032

Studieregistreringsdatum

Först inskickad

19 november 2025

Först inskickad som uppfyllde QC-kriterierna

26 november 2025

Första postat (Faktisk)

8 december 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

23 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

22 september 2026

Senast verifierad

1 september 2026

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera